MediciNova participates in RECEDE Phase 3 trial
MediciNova announced its participation at the Kick-off Meeting for the Phase 3 trial, "REgeneration in CErvical DEgenerative Myelopathy", a collaboration with University of Cambridge researchers, as well as at the first UK Academic Spine Symposium, which took place on Tuesday, May 7, 2019 at the Royal Society of Medicine in London, UK. Following the events, Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer gave a speech for the official launch of Myelopathy.org hosted by Lord Carter of Coles in the UK Parliament House of Lords on supporting innovative science through its collaboration in the RECEDE Myelopathy Phase 3 trial to evaluate MN-166 (ibudilast) in degenerative cervical myelopathy patients. Fellow speakers included H.E. Mr. Koji Tsuruoka, Ambassador Extraordinary and Plenipotentiary, Embassy of Japan in the UK as well as world-renown Spine Surgeon and Researcher, Professor Michael Fehlings, M.D., Ph.D., Vice-Chair Research for the Department of Surgery at the University of Toronto. The RECEDE Myelopathy Phase 3 trial is being conducted under an agreement between MediciNova, the University of Cambridge, and Cambridge University Hospitals NHS Foundation Trust. Funding for the trial is being provided by the United Kingdom National Institute for Health Research. Its Chief Investigator is Mark Kotter, M.D., Ph.D., NIHR Clinician Scientist and Consultant in Neurosurgery at the University of Cambridge. The trial will evaluate MN-166 as an adjuvant treatment for DCM following spinal surgery and determine whether MN-166 is more effective than placebo in improving outcomes.